MX388321B - Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. - Google Patents
Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.Info
- Publication number
- MX388321B MX388321B MX2017004600A MX2017004600A MX388321B MX 388321 B MX388321 B MX 388321B MX 2017004600 A MX2017004600 A MX 2017004600A MX 2017004600 A MX2017004600 A MX 2017004600A MX 388321 B MX388321 B MX 388321B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- treatment
- aminopurines
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060339P | 2014-10-06 | 2014-10-06 | |
| PCT/US2015/053941 WO2016057370A1 (en) | 2014-10-06 | 2015-10-05 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017004600A MX2017004600A (es) | 2017-06-30 |
| MX388321B true MX388321B (es) | 2025-03-19 |
Family
ID=55632334
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004600A MX388321B (es) | 2014-10-06 | 2015-10-05 | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. |
| MX2021014531A MX2021014531A (es) | 2014-10-06 | 2017-04-06 | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014531A MX2021014531A (es) | 2014-10-06 | 2017-04-06 | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US9512124B2 (show.php) |
| EP (2) | EP3822274B1 (show.php) |
| JP (4) | JP6884701B2 (show.php) |
| KR (2) | KR102504849B1 (show.php) |
| CN (2) | CN113248506A (show.php) |
| AR (2) | AR102171A1 (show.php) |
| AU (2) | AU2015328414B2 (show.php) |
| CA (1) | CA2963639C (show.php) |
| CL (1) | CL2017000820A1 (show.php) |
| CO (1) | CO2017003838A2 (show.php) |
| CY (1) | CY1124173T1 (show.php) |
| DK (1) | DK3204386T3 (show.php) |
| EA (1) | EA201790779A1 (show.php) |
| EC (1) | ECSP17026210A (show.php) |
| ES (2) | ES2980464T3 (show.php) |
| HR (1) | HRP20210656T1 (show.php) |
| HU (1) | HUE054694T2 (show.php) |
| IL (2) | IL251566B (show.php) |
| LT (1) | LT3204386T (show.php) |
| MX (2) | MX388321B (show.php) |
| PL (1) | PL3204386T3 (show.php) |
| PT (1) | PT3204386T (show.php) |
| RS (1) | RS61884B1 (show.php) |
| SG (2) | SG10202009598VA (show.php) |
| SI (1) | SI3204386T1 (show.php) |
| SM (1) | SMT202100302T1 (show.php) |
| TW (1) | TW201629063A (show.php) |
| WO (1) | WO2016057370A1 (show.php) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20210656T1 (hr) * | 2014-10-06 | 2021-07-23 | Signal Pharmaceuticals, Llc | Supstituirani spojevi aminopurina, njihovi sastavi, te postupci liječenja istima |
| WO2016100308A1 (en) | 2014-12-16 | 2016-06-23 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-jun n-terminal kinase in skin |
| EP3250557B1 (en) | 2015-01-29 | 2024-11-20 | Signal Pharmaceuticals, LLC | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| CN107567450B (zh) | 2015-03-18 | 2020-03-13 | 百时美施贵宝公司 | 用作tnf抑制剂的杂环化合物 |
| WO2016149436A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| BR112017019731A2 (pt) | 2015-03-18 | 2018-05-22 | Bristol-Myers Squibb Company | compostos heterocíclicos tricíclicos úteis como inibidores de tnf |
| MX385379B (es) | 2015-07-24 | 2025-03-18 | Celgene Corp | Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilciclohexanol e intermedios utiles en este. |
| AU2016301215A1 (en) | 2015-08-03 | 2018-03-22 | Bristol-Myers Squibb Company | Cyclic compounds useful as modulators of TNF alpha |
| EP3845536A1 (en) * | 2016-04-01 | 2021-07-07 | Signal Pharmaceuticals, LLC | Solid forms of (1s,4s)-4-(2-(((3s4r)-3-fluorotetrahydro-2h-pyran-4-yl) amino)-8-((2,4,6-trichlorophenyl) amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use |
| JP7014731B2 (ja) | 2016-04-01 | 2022-02-01 | シグナル ファーマシューティカルズ，エルエルシー | 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法 |
| ES2926149T3 (es) * | 2016-06-02 | 2022-10-24 | Celgene Corp | Agentes antipalúdicos animales y humanos |
| AR108665A1 (es) * | 2016-06-02 | 2018-09-12 | Celgene Corp | Derivados de aminopurina como agentes anti-tripanosómicos y anti-leishmania |
| CN111417634A (zh) * | 2017-10-04 | 2020-07-14 | 细胞基因公司 | 用于制备顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的方法 |
| CA3078368A1 (en) | 2017-10-04 | 2019-04-11 | Celgene Corporation | Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide |
| TW202202498A (zh) * | 2020-07-01 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | 一種並環雜環衍生物及其在醫藥上的應用 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| CN114478326B (zh) * | 2022-01-21 | 2023-10-03 | 安徽宁亿泰科技有限公司 | 一种苯嘧磺草胺关键中间体的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| US7672705B2 (en) * | 2004-07-19 | 2010-03-02 | Resonant Medical, Inc. | Weighted surface-to-surface mapping |
| US7759342B2 (en) * | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| US7723340B2 (en) * | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| EP1951693A4 (en) | 2005-11-18 | 2012-05-30 | Astrazeneca Ab | SOLID FORMULATIONS |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| NZ589053A (en) | 2006-10-27 | 2012-03-30 | Signal Pharm Llc | Process of preparing 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds |
| WO2009130342A1 (es) | 2008-04-23 | 2009-10-29 | Farmasierra Manufacturing, S.L. | Formulación farmacéutica mejorada a base de ibuprofeno y codeína |
| US20130034495A1 (en) | 2009-12-09 | 2013-02-07 | Marie Georges Beauchamps | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8680076B2 (en) * | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US20160082015A1 (en) | 2013-04-18 | 2016-03-24 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| HRP20210656T1 (hr) | 2014-10-06 | 2021-07-23 | Signal Pharmaceuticals, Llc | Supstituirani spojevi aminopurina, njihovi sastavi, te postupci liječenja istima |
| EP3845536A1 (en) | 2016-04-01 | 2021-07-07 | Signal Pharmaceuticals, LLC | Solid forms of (1s,4s)-4-(2-(((3s4r)-3-fluorotetrahydro-2h-pyran-4-yl) amino)-8-((2,4,6-trichlorophenyl) amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use |
-
2015
- 2015-10-05 HR HRP20210656TT patent/HRP20210656T1/hr unknown
- 2015-10-05 SG SG10202009598VA patent/SG10202009598VA/en unknown
- 2015-10-05 EP EP20214685.8A patent/EP3822274B1/en active Active
- 2015-10-05 ES ES20214685T patent/ES2980464T3/es active Active
- 2015-10-05 AR ARP150103202A patent/AR102171A1/es not_active Application Discontinuation
- 2015-10-05 EA EA201790779A patent/EA201790779A1/ru unknown
- 2015-10-05 KR KR1020177010551A patent/KR102504849B1/ko active Active
- 2015-10-05 SG SG11201702759XA patent/SG11201702759XA/en unknown
- 2015-10-05 PL PL15848476T patent/PL3204386T3/pl unknown
- 2015-10-05 HU HUE15848476A patent/HUE054694T2/hu unknown
- 2015-10-05 DK DK15848476.6T patent/DK3204386T3/da active
- 2015-10-05 CA CA2963639A patent/CA2963639C/en active Active
- 2015-10-05 WO PCT/US2015/053941 patent/WO2016057370A1/en not_active Ceased
- 2015-10-05 JP JP2017538172A patent/JP6884701B2/ja active Active
- 2015-10-05 CN CN202110381676.XA patent/CN113248506A/zh active Pending
- 2015-10-05 LT LTEP15848476.6T patent/LT3204386T/lt unknown
- 2015-10-05 SI SI201531584T patent/SI3204386T1/sl unknown
- 2015-10-05 ES ES15848476T patent/ES2871142T3/es active Active
- 2015-10-05 CN CN201580065272.2A patent/CN107001372B/zh active Active
- 2015-10-05 TW TW104132732A patent/TW201629063A/zh unknown
- 2015-10-05 SM SM20210302T patent/SMT202100302T1/it unknown
- 2015-10-05 US US14/874,513 patent/US9512124B2/en active Active
- 2015-10-05 PT PT158484766T patent/PT3204386T/pt unknown
- 2015-10-05 MX MX2017004600A patent/MX388321B/es unknown
- 2015-10-05 AU AU2015328414A patent/AU2015328414B2/en active Active
- 2015-10-05 KR KR1020237006598A patent/KR20230035424A/ko not_active Withdrawn
- 2015-10-05 RS RS20210632A patent/RS61884B1/sr unknown
- 2015-10-05 EP EP15848476.6A patent/EP3204386B1/en active Active
-
2016
- 2016-10-27 US US15/335,619 patent/US9737541B2/en active Active
-
2017
- 2017-04-04 CL CL2017000820A patent/CL2017000820A1/es unknown
- 2017-04-04 IL IL251566A patent/IL251566B/en active IP Right Grant
- 2017-04-06 MX MX2021014531A patent/MX2021014531A/es unknown
- 2017-04-20 CO CONC2017/0003838A patent/CO2017003838A2/es unknown
- 2017-04-27 EC ECIEPI201726210A patent/ECSP17026210A/es unknown
- 2017-07-05 US US15/641,383 patent/US10149849B2/en active Active
-
2018
- 2018-10-24 US US16/169,414 patent/US10398700B2/en active Active
-
2019
- 2019-07-17 US US16/514,749 patent/US10646493B2/en active Active
- 2019-10-02 JP JP2019182133A patent/JP6987823B2/ja active Active
-
2020
- 2020-02-28 AU AU2020201486A patent/AU2020201486B2/en active Active
- 2020-04-13 US US16/846,503 patent/US10940152B2/en active Active
- 2020-09-01 IL IL277069A patent/IL277069B/en unknown
-
2021
- 2021-01-12 US US17/147,127 patent/US11590139B2/en active Active
- 2021-05-24 CY CY20211100444T patent/CY1124173T1/el unknown
- 2021-12-01 JP JP2021195105A patent/JP7196270B2/ja active Active
-
2022
- 2022-12-14 JP JP2022199122A patent/JP2023027269A/ja active Pending
-
2023
- 2023-01-11 US US18/095,670 patent/US20230158035A1/en not_active Abandoned
- 2023-03-09 AR ARP230100589A patent/AR128748A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX388321B (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| PH12015502443A1 (en) | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| CL2018001230A1 (es) | Tratamiento de osteoartritis | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| MX2018007774A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| GEP20186933B (en) | Substituted dihydroisoquinoline compounds | |
| MX376106B (es) | Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infección por virus de hepatitis b. | |
| EA201791563A1 (ru) | Замещенные нуклеозидные производные, полезные в качестве агентов против рака | |
| MX373247B (es) | Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina. | |
| MX373935B (es) | Compuestos antiproliferativos y métodos de uso de los mismos. | |
| EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
| DOP2016000299A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 | |
| MX2016014728A (es) | Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b. | |
| MX2016011992A (es) | Derivados de piperidina-diona. | |
| TN2017000544A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| MX2018008095A (es) | Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih. | |
| JOP20190254A1 (ar) | مركبات مضادة للأورام | |
| MX2018000280A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX390051B (es) | Antagonistas de ep4. | |
| EA201691566A1 (ru) | Применение производных пиридазина для предупреждения или лечения атаксического синдрома | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы |